Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease

Pharmacological inhibition of CCR9 is a novel approach in the treatment of inflammatory bowel disease

Bibliográfalaš dieđut
Váldodahkkit:	Bekker, P, Keshav, S, Wei, Z, Ertl, L, Wang, Y, Lai, N, Wright, J, Ungashe, S, Schall, T
Materiálatiipa:	Journal article
Almmustuhtton:	2007

Geahča maid

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
Dahkki: Walters, M, et al.
Almmustuhtton: (2010)

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
Dahkki: Keshav, S, et al.
Almmustuhtton: (2007)

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Dahkki: Bekker, P, et al.
Almmustuhtton: (2007)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease.
Dahkki: Wendt, E, et al.
Almmustuhtton: (2015)

CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
Dahkki: Wendt E, et al.
Almmustuhtton: (2015-04-01)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
Dahkki: Ungashe, S, et al.
Almmustuhtton: (2008)

Cc chemokine receptor 9 (ccr9) antagonist ameliorates experimental ileitis and colitis
Dahkki: Wei, Z, et al.
Almmustuhtton: (2005)

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
Dahkki: Bekker, P, et al.
Almmustuhtton: (2008)

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
Dahkki: Bekker, P, et al.
Almmustuhtton: (2008)

CCR9 Antagonists in the Treatment of Ulcerative Colitis
Dahkki: Pirow Bekker, et al.
Almmustuhtton: (2015-01-01)

Pharmacological inhibition of the inflammatory receptor CCR2 relieves the early deleterious consequences of status epilepticus
Dahkki: Carlos Alemán-Ruiz, et al.
Almmustuhtton: (2023-04-01)

EXPRESSION OF LYSOZYME IN INFLAMMATORY BOWEL-DISEASE
Dahkki: Stamp, G, et al.
Almmustuhtton: (1990)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
Dahkki: Cristiano Pagnini, et al.
Almmustuhtton: (2019-06-01)

Pharmacologic therapy for inflammatory bowel disease refractory to steroids
Dahkki: Martínez-Montiel MP, et al.
Almmustuhtton: (2015-08-01)

A systems pharmacology model for inflammatory bowel disease.
Dahkki: Violeta Balbas-Martinez, et al.
Almmustuhtton: (2018-01-01)

Lysozyme gene expression in inflammatory bowel disease.
Dahkki: Stamp, G, et al.
Almmustuhtton: (1992)

Therapeutic potential of an anti-CCR9 mAb evidenced in xenografts of human CCR9+ tumors
Dahkki: Silvia Santamaria, et al.
Almmustuhtton: (2022-07-01)

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
Dahkki: Bekker, P, et al.
Almmustuhtton: (2009)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
Dahkki: Keshav, S, et al.
Almmustuhtton: (2009)

Role of periostin in inflammatory bowel disease development and synergistic effects mediated by the CCL5–CCR5 axis
Dahkki: Saida Mukanova, et al.
Almmustuhtton: (2022-10-01)

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
Dahkki: Satish Keshav, et al.
Almmustuhtton: (2013-01-01)

NLRP3 inflammasome inhibition of OP9 cells enhance therapy for inflammatory bowel disease
Dahkki: Yutong Chen, et al.
Almmustuhtton: (2023-07-01)

Pharmacological Inhibition of CCR2 Signaling Exacerbates Exercise-Induced Inflammation Independently of Neutrophil Infiltration and Oxidative Stress
Dahkki: Takaki Tominaga, et al.
Almmustuhtton: (2021-12-01)

CCR5 Delta 32 polymorphism in inflammatory bowel disease: Further association with ulcerative colitis and with primary sclerosing cholangitis.
Dahkki: Satsangi, J, et al.
Almmustuhtton: (2000)

Phosphoinositide signalling in inflammatory bowel disease and colorectal neoplasia
Dahkki: Osborne, C, et al.
Almmustuhtton: (2002)

Pharmacologic Management of Monogenic and Very Early Onset Inflammatory Bowel Diseases
Dahkki: Anne E. Levine, et al.
Almmustuhtton: (2023-03-01)

Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease
Dahkki: Yang Zheng, et al.
Almmustuhtton: (2021-11-01)

Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis
Dahkki: Leo R. Fitzpatrick
Almmustuhtton: (2012-01-01)

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
Dahkki: Keshav, S, et al.
Almmustuhtton: (2007)

How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?
Dahkki: Ghislain Opdenakker, et al.
Almmustuhtton: (2022-09-01)

Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease
Dahkki: Magali de Bruyn, et al.
Almmustuhtton: (2017-05-01)

A systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte trafficking.
Dahkki: Noah J Tubo, et al.
Almmustuhtton: (2012-01-01)

Management of Irritable Bowel Syndrome: Novel Approaches to the Pharmacology of Gut Motility
Dahkki: Carmelo Scarpignato, et al.
Almmustuhtton: (1999-01-01)

Growth Factors in Inflammatory Bowel Disease
Dahkki: Nicholas Wright
Almmustuhtton: (1996-01-01)

CCR9 axis inhibition enhances hepatic migration of plasmacytoid DCs and protects against liver injury
Dahkki: Yuzo Koda, et al.
Almmustuhtton: (2022-09-01)

Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease.
Dahkki: William C Reisdorf, et al.
Almmustuhtton: (2019-01-01)

The role of CCL25 and CCR9 in intestinal inflammation
Dahkki: Wendt, E, et al.
Almmustuhtton: (2013)

CCR9 in cancer: oncogenic role and therapeutic targeting
Dahkki: Zhenbo Tu, et al.
Almmustuhtton: (2016-02-01)

Inhibition of inflammatory CCR2 signaling promotes aged muscle regeneration and strength recovery after injury
Dahkki: Roméo S. Blanc, et al.
Almmustuhtton: (2020-08-01)

CCR9 Expressing T Helper and T Follicular Helper Cells Exhibit Site-Specific Identities During Inflammatory Disease
Dahkki: Ilaria Cosorich, et al.
Almmustuhtton: (2019-01-01)